Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16574104 | 0.92 | MAP4K4 (0.48) | MAP4K4PTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL16574075 | 0.89 | MAP4K4 (0.46) | MAP4K4PTGS2PTGS1IDO1CYP3A4 | |
| SCHEMBL16574098 | 0.89 | MAP4K4 (0.48) | MAP4K4PTGS2PTGS1IDO1CYP3A4 | |
| SCHEMBL16574091 | 0.87 | SLC1A3 (0.51) | MAP4K4PTGS2PTGS1IDO1CYP3A4 | |
| SCHEMBL16574082 | 0.84 | MAP4K4 (0.50) | MAP4K4PTGS2PTGS1IDO1CYP3A4 | |
| SCHEMBL16574156 | 0.82 | L3MBTL1 (0.48) | MAP4K4PTGS2IDO1CYP3A4ABL1 | |
| SCHEMBL12365163 | 0.82 | ABL1 (0.50) | PTGS2AKR1C3AKR1C2ABL1 | |
| SCHEMBL16574093 | 0.82 | MAP4K4 (0.51) | MAP4K4PTGS2PTGS1IDO1CYP3A4 | |
| SCHEMBL13176931 | 0.81 | MAP4K4 (0.50) | MAP4K4IDO1CYP3A4ABL1 | |
| SCHEMBL16574103 | 0.81 | MPL (0.43) | MAP4K4AKR1C3AKR1C2IDO1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2018-04-05 | — | — | US | disclosed |
| US-9750740-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | Kanos Pharmaceuticals, Inc. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2017-04-06 | — | — | US | disclosed |
| US-9512122-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | KAROS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160096836-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2016-04-07 | — | — | US | disclosed |
| US-9199994-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | KAROS PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150080393-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080393-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | MAP4K4 1548/4885PTGS2 645/4885PTGS1 125/4885 |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | MAP4K4 1548/4885PTGS2 645/4885PTGS1 125/4885 |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | MAP4K4 1548/4885PTGS2 645/4885PTGS1 125/4885 |
| US-20160096836-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | MAP4K4 1548/4885PTGS2 645/4885PTGS1 125/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | MAP4K4 1548/4885PTGS2 645/4885PTGS1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.